Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 244

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 244
---
 regarding final composition of share premium in each scenario, see section “ Share premium.” (3)Reflects the exchange of Sponsor Shares (4,312,500 Class B ordinary shares) for Company Shares, considering the par value of $0.0001 per share, as part of the Business Combination. Therefore, the net adjustment in share capital results from: (i) the elimination of APx’s share capital for $431.25 for consolidation purposes; and (ii) recognition of Company Shares to be issued to Sponsor shareholders for $431.25. Additionally, the adjustment in share premium results from recognition of share premium derived from the issuance of Company Shares to Sponsor shareholders for ($5,753,525) (considering the difference between the book value of the net assets of APx before considering the adjustment described in Note (2), (which amounts to $5,753,094) and the par value of $431.25 of the Company Shares issued). For more detailed information regarding final composition of share premium in each scenario, see section “ Share premium.” Finally, the adjustment in Accumulated deficit includes the elimination of APx’s accumulated deficit of $5,753,525 for consolidation purposes. (4)Represents the preliminary estimated transaction costs to be incurred by OmnigenicsAI for approximately $3.33 million. Said amount of $3.33 million, is reflected as an adjustment between: (a)share premium for the cost specifically attributable to the issue of new shares (using a criteria of percentage of shares issued) by $0.46 million, $0.43 million and $0.41 million, in scenarios1, 2 and3, respectively (for more detailed information regarding final composition of Share premium in each scenario, see section “ Share premium”); and (b)the remaining amount in the Pro Forma Combined Consolidated Statement of Operations for the year ended June 30, 2024, under “General and administrative expenses” by $2.87 million, $2.90 million and $2.92 million, in scenarios1, 2 and3, respectively. Consequently, these figures allocated to the Pro Forma Combined Consolidated Statement of Operations are also disclosed as an adjustment in the “Accumulated Deficit” line of the Pro Forma Combined Consolidated Statement of Financial Position as of June 30, 2024. See Note (1) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Operations for the Year Ended June 30